Dr. Mireille is a Paediatric Endocrinologist at Al Jalila Children’s. She graduated from the American University of Beirut in 2010 and completed her training as a paediatrician in the US at Wayne State University in Michigan. She subsequently pursued a paediatric endocrinology fellowship at Emory University. She holds the American Board of General Pediatrics and Pediatric Endocrinology. She is a Fellow of the American Academy of Pediatrics and a member of the Pediatric Endocrine Society. Dr. El Bejjani has presented at international and national conferences as an expert in her field. Her role involves caring for children with diabetes, hormonal disturbances and growth problems. She is committed to providing them with the best medical care through an individualized approach to each patient that takes into account their social and emotional needs, and shared decision making that empowers patients and their families.
Dr. Nandu Thalange is Consultant Paediatric Endocrinologist at Al Jalila Children’s and graduated from King’s College, London in 1988, intent on a career in paediatric endocrinology. After junior posts at King’s College Hospital and other hospitals around London, he moved to the Royal Manchester Children’s Hospital to take up a research training post in paediatric endocrinology. His research at that time was focused primarily on the physiology of normal and abnormal growth and culminated in 3 significant papers in the Journal of Clinical Endocrinology and Metabolism, Pediatric Research and Archives of Diseases of Childhood.
After completing his research post, Dr. Nandu moved to East Anglia, completing his training in Norwich and Cambridge, including a year in child public health. In 2002, Nandu took up a post as a Consultant Paediatric Endocrinologist at the Norfolk and Norwich University Hospital in East Anglia, until he left in April 2017. He ran a large paediatric endocrinology, diabetes and weight management service, including specialist clinics for neurofibromatosis, achondroplasia and bone disease, notably osteoporosis and osteogenesis imperfecta. The diabetes service had over 350 children and adolescents with diabetes (including 60% on insulin pumps), and achieved excellent results in the National Diabetes Audit.
Dr. Nandu has been an investigator in a number of collaborative multicentre research studies, in diabetes and endocrinology, including being chief investigator for the international multi-centre trials that led to the approval of insulin detemir and insulin degludec in children, worldwide. His other research interests include hypertension, (he co-authored a paper on the normal ranges for blood pressure in Great Britain, based on an analysis of over 20000 children and young adults), psychological impacts of disease, epidemiology, and child public health, particularly avoidable child mortality. He is a public speaker and frequently presents to international audiences.